ANI Pharmaceuticals, Inc.
ANIP
$63.26
$1.863.03%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.48% | 7.46% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.48% | 7.46% | |||
| Cost of Revenue | 27.28% | 9.32% | |||
| Gross Profit | 29.37% | 6.12% | |||
| SG&A Expenses | -1.08% | 42.20% | |||
| Depreciation & Amortization | 43.51% | 7.15% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.73% | 23.32% | |||
| Operating Income | 114.04% | -222.02% | |||
| Income Before Tax | 56.31% | -1,277.26% | |||
| Income Tax Expenses | 52.45% | -- | |||
| Earnings from Continuing Operations | 57.48% | -956.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 57.48% | -956.67% | |||
| EBIT | 114.04% | -222.02% | |||
| EBITDA | 397.10% | -79.45% | |||
| EPS Basic | 56.62% | -2,652.83% | |||
| Normalized Basic EPS | 62.86% | -475.17% | |||
| EPS Diluted | 56.75% | -2,660.87% | |||
| Normalized Diluted EPS | 62.86% | -475.17% | |||
| Average Basic Shares Outstanding | 0.22% | 0.43% | |||
| Average Diluted Shares Outstanding | 0.22% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -1.35% | 0.91% | |||
